<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05115552</url>
  </required_header>
  <id_info>
    <org_study_id>Urocortin 2 Biomarker</org_study_id>
    <nct_id>NCT05115552</nct_id>
  </id_info>
  <brief_title>Comparison Between Urocortin 2 and Brain Type Natriuretic Peptide</brief_title>
  <official_title>Comparison Between Urocortin 2 and Brain Type Natriuretic Peptide as a Biomarker in Patients With Acute Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Evaluation of the role of serum urocortin 2 levels in acute decompensated HF patients&#xD;
           and their association with clinical and echocardiographic findings.&#xD;
&#xD;
        2. Assessment of the clinical utility of urocortin 2 in monitoring AHF patients.&#xD;
&#xD;
        3. Comparison between urocortin 2 and BNP as a biomarker in AHF patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure (HF) is a clinical syndrome with symptoms and/or signs caused by a structural&#xD;
      and/ or functional cardiac abnormality and corroborated by elevated natriuretic peptide&#xD;
      levels and/or objective evidence of pulmonary or systemic congestion. (1) .The&#xD;
      pathophysiology of HF is a complex interplay of genetic and multiple molecular mechanisms&#xD;
      (from inï¬‚ammation to hormonal pathways) performing in the composite network of the&#xD;
      cardiovascular system environment. (2).&#xD;
&#xD;
      Monitoring of biomarkers in HF can be used to make an initial diagnosis, to aid in prognostic&#xD;
      stratification, and to identify a patient's response to therapeutic intervention. (3).&#xD;
&#xD;
      Natriuretic peptide (NP) concentrations are quantitative plasma biomarkers for the presence&#xD;
      and severity of haemo-dynamic cardiac stress and heart failure. (4). That facilitate renal&#xD;
      filtration and sodium excretion whilst suppressing the vasoconstrictor sodium, retaining&#xD;
      Renin angiotensin aldosterone system and exerting a tonic anti-trophic effect. (5). But the&#xD;
      natriuretic peptide levels are significantly affected by weight, the NT- proBNP in obese&#xD;
      subjects is much lower than normal weight subjects. (6). Other factors that affect BNP levels&#xD;
      including gender, age and renal disease&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the role of serum urocortin 2 levels</measure>
    <time_frame>baseline</time_frame>
    <description>Evaluation of the role of serum urocortin 2 levels in acute decompensated HF patients and their association with clinical and echocardiographic findings.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the clinical utility of urocortin 2 in monitoring AHF patients</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison between urocortin 2 and BNP</measure>
    <time_frame>baseline</time_frame>
    <description>Comparison between urocortin 2 and BNP as a biomarker in AHF patients(which is more specific for AHF patients )</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Urocortin 2</condition>
  <eligibility>
    <study_pop>
      <textblock>
        both gender above 18 years old with acute decompensated heart failure without ACS or stroke&#xD;
        in the past 3 months or severe valvular disease or severe CKD .&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with acute decompensated heart failure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute coronary syndrome or stroke in the past 3 months.&#xD;
&#xD;
          -  Severe chronic kidney disease.&#xD;
&#xD;
          -  Severe valve disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christen S. Welliam, resident</last_name>
    <phone>01283938578</phone>
    <email>christeensaad50@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Madleen A. Attia, professor</last_name>
    <phone>0127022028</phone>
    <email>Madleen2001@yahoo.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>October 30, 2021</last_update_submitted>
  <last_update_submitted_qc>October 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Christen Saad Welliam</investigator_full_name>
    <investigator_title>resident</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

